ArticleFrontiers in pharmacology2026
Mechanism of
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethnopharmacological Relevance: The medicinal relevance of Aim: A systematic assessment of the antitumor potential and the underlying molecular mechanisms of Materials and Methods: UHPLC-Q-Exactive HRMS and literature mining were used to identify bioactive constituents of Results: 49 bioactive compounds and 169 overlapping targets of RCC were found. Based on target interactions, cerevisterol, withanolide, inonoterpene A and polyporusterone D were found to be major constituents. Network analysis and docking studies identified AKT1, EGFR, CTNNB1, STAT3, and BCL2 as core targets, exhibiting strong binding affinities with key compounds. The PI3K/Akt/mTOR and other cancer-related pathways were identified to be engaged in functional enrichment. EEIH treatment considerably inhibited RCC cell proliferation, colony formation, and migration, triggering apoptosis and downregulating phosphorylated Akt and mTOR. The Conclusion: The antitumor mechanism of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.